Member Info for Walkley

Last RNS said results would be posted on 21 April. Shouldn't the company have given a new date.

Does anyone have a view as to the "right" price For NEW Galliford Try? Up 45% from 137p on 28 January.

Sudden upwards spike today -. Are some major software companies finally thinking about a bid ?

“With current visibility and a significant and growing pipeline, the Company issues FY19 revenue guidance of $24m.” Half year report 25 Sept 2019
“The Company has good visibility into renewals and a growing pipeline of late-stage deals with strategic partners during the second half and reiterates its revenue guidance given on 25 September 2019 for the 2019 financial year.” 25 November 2019 - Subscription for shares at 425p

“Revenue for the year ended 31 December 2019 is expected to be approximately $16 million” 4 Feb Trading statement
To be $8m (33% of whole year) out with only a month to go takes some doing!
Interested in the product but think will watch for a while!

How much are the European elections worth to Idox?

10-year supply and distribution agreement with BayWa Agri Supply and Trade B.V. ("BAST"), a wholly owned subsidiary of BayWa AG

§ BayWa AG is a leading European integrated agribusiness with extensive commercial and logistics platform with direct access to the farmgate across Europe

§ Guaranteed minimum volumes ramping up to 2.5 Mtpa in year five - taking Sirius aggregate peak contracted sales volume to 10.7Mtpa (12.1 Mtpa with customer options)

§ Agreement provides Sirius with greater downstream pricing exposure in the premium European market and is expected to deliver highest pricing across current portfolio

Sales at John Lewis last week were down 13.7% on previous year. Yes, I know Easter has moved but first 9 weeks they are down 4.8%.

Debenhams sales figures will be horrendous.

"Expectation is that from these efforts will materialise a value creating deal in the near term."

Before cash runs out I hope!

UK and international figures are transposed on the release shown on this web site but correct on the London Stock Exchange -how many other reports does lse.co.uk get wrong?

Department stores are having it tough. John Lewis sales for last 5 weeks only up 1.3% on last year (5.8% on 2016). But last week fashion -which should be Debenhams' strength was 11.4% up on last year (week ending 4th Sept). -with womenswear +21.7%

Seconded!

Where did you get the Sept date from? Why are the half year results delayed ? Is that why the share price is going down?

39p traded first thing

and in the right direction!!

Soros Fund management have bought 7% of IDOX

LSE haven't posted this RNS from yesterday:

"Oxford, UK, and Cambridge, MA, US, 10 July 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces it has been awarded up to $4.5 million from CARB-X, a public-private partnership devoted to accelerating early antibiotic research and development. This award will be used to support Summit’s wholly-owned, lead series of new mechanism antibiotic compounds for gonorrhoea. Gonorrhoea is recognised as an urgent bacterial threat by the US Centers for Disease Control (‘CDC’) due to the diminishing treatment arsenal. There is currently only one treatment option for gonorrhoea recommended by the CDC.2

Summit tweeted that will be at ParentProjectMD to answer questions about Phaseout DMD tomorrow. They will be very disappointed.

If Redmoor don't fund their share then SML will pay for it and get a larger percent of the operation.

"New Age Exploration Ltd (ASX:NAE) has been granted a trading halt by the ASX ahead of a material capital raising" from their website

"The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy ('DMD'). These interim data showed a statistically significant and meaningful reduction in both muscle damage and muscle inflammation after just 24 weeks of treatment. Should these changes be sustained after 48 weeks of treatment, we believe we will be positioned to pursue an accelerated path to regulatory approval for ezutromid. We look forward to the full trial results in the third quarter of this year."